WVU in the News: Novo Nordisk cuts Wegovy prices again

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance.

The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to patients paying the full bill. That’s down from $499, and in line with terms of a drug pricing agreement outlined earlier this month by President Donald Trump’s administration.

Dr. Laura Davisson said the medication would still be unaffordable for patients on Medicaid in states where the government-funded program for people with low incomes doesn’t cover the drug.

The bigger issue is expanding coverage of the treatments, said Davisson, a West Virginia University obesity specialist.